ITMCTR2023000062尚未招募Unknown
Demonstration study on clinical evaluation of advantageous diseases in ethnic minority medicine based on evidence-based medicine support system
Tibetan Hospital of Xizang Autonomous Region0 个研究点开始时间: 待定最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 75(—)
- 性别
- All
入选标准
- •1. Age range from 18 to 75 years old (including both ends), regardless of gender.
- •2. Those who meet the diagnostic criteria for rheumatoid arthritis in Western medicine during screening.
- •3. When screening, it meets the differentiation criteria for Tibetan medicine Changzhong cold syndrome.
- •4. During screening, it was diagnosed as moderate to low-grade active rheumatoid arthritis (2.6 = baseline DAS28-CRP score = 5.1).
- •5. Voluntarily sign an informed consent form.
排除标准
- •1. Patients with other rheumatic and immune diseases.
- •2. Patients with severe cardiovascular and cerebrovascular diseases, kidney disease, and liver disease.
- •3. Patients with severe infections, tumors, and infectious skin diseases.
- •4. Patients with late stage deformities, disabilities, or loss of labor in rheumatoid arthritis.
- •5. Patients with obvious skin lesions and ulcers in the affected area of the joint.
- •6. Individuals who are allergic to alcohol or experimental drugs.
- •7. Pregnant or lactating women, or those who are at risk of conception but have not taken effective contraceptive measures during the trial period.
- •8. Subjects with severe organic lesions, mental disorders, or other reasons who are unable to cooperate with treatment.
- •9. Those who have used biological agents in the past 3 months.
- •10. Those who have been participating in other clinical trials for the past month or are currently participating.
研究者
相似试验
尚未招募
1 期
Clinical study for the first-line treatment of advanced hepatocellular carcinoma with anrotinib hydrochloride capsuleHepatocellular carcinomaITMCTR1900002329Guilin Traditional Chinese Medicine Hospital
已完成
不适用
clinical study for evaluation of the diagnostic value of I-FABP (intestinal fatty-acid binding protein) in the diagnostic workup of mesenteric ischemia in ICU- patientsK55.0Acute vascular disorders of intestineDRKS00010524niversitätsklinikum Jena43
Unknown
不适用
Adaprev in Digital Flexor Tendon RepairTendon InjuriesNCT01014494Renovo44
已完成
不适用
The role of stem cells in hypertrophic scar improvementHypertrophic Scar.Hypertrophic scarIRCT2012070710201N1Tehran University Of Medical Sciences60
Unknown
不适用
A Explorative Study to Evaluate the Clinical Feasibility of AVATAMEDGlioblastomaNCT04313842Doo-Sik Kong40
